The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007

CONTEXT: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. S...

Descripción completa

Detalles Bibliográficos
Autor principal: Schwartz, David A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727774/
https://www.ncbi.nlm.nih.gov/pubmed/19707435
_version_ 1782170695939129344
author Schwartz, David A
author_facet Schwartz, David A
author_sort Schwartz, David A
collection PubMed
description CONTEXT: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment Evaluation in Crohn’s Disease Safety and Efficacy) 2 trial of certolizumab pegol in patients with Crohn’s disease.
format Text
id pubmed-2727774
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27277742009-08-25 The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007 Schwartz, David A Biologics Review CONTEXT: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment Evaluation in Crohn’s Disease Safety and Efficacy) 2 trial of certolizumab pegol in patients with Crohn’s disease. Dove Medical Press 2008-03 2008-03 /pmc/articles/PMC2727774/ /pubmed/19707435 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Schwartz, David A
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title_full The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title_fullStr The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title_full_unstemmed The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title_short The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007
title_sort precise 2 trial of certolizumab pegol, a new pegylated anti-tnf agent, in the treatment of crohn’s disease: an interview with david a schwartz, 13 june 2007
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727774/
https://www.ncbi.nlm.nih.gov/pubmed/19707435
work_keys_str_mv AT schwartzdavida theprecise2trialofcertolizumabpegolanewpegylatedantitnfagentinthetreatmentofcrohnsdiseaseaninterviewwithdavidaschwartz13june2007
AT schwartzdavida precise2trialofcertolizumabpegolanewpegylatedantitnfagentinthetreatmentofcrohnsdiseaseaninterviewwithdavidaschwartz13june2007

Ejemplares similares